Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
domingo, 19 de abril de 2026
Humanity first, not country first The Lancet Regional Health – Europe + +... ++ +...
The effectiveness of psychosocial interventions for self-harm in males compared to females: a systematic review and meta-analysis
Oliver Matias Oliver.Matias@citystgeorges.ac.uk ∙ Alexandra E. Bakou ∙ Kirsten Barnicot ∙ Rose McCabe
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00018-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-_6QghD46vbVyE0L1AwSpldCO9iYyG-U0C7iKQk0oYrtVqrUuzCAC1_93ylRZN_kH_fimm7B5n0xzl2HiMz8tgC4ifdRw&_hsmi=413587672&utm_content=413506161&utm_source=hs_email
Cutting-edge systemic cancer therapies
Executive summary
Systemic cancer therapies are undergoing rapid transformation, redefining precision and durability in oncologic treatment. This Series examines advances across antibody–drug conjugates, cell therapies, multispecific antibodies, and immunologically driven strategies such as oncolytic viruses and cancer vaccines. It highlights how innovations in molecular design, conjugation technologies, and antibody engineering are expanding therapeutic potential while introducing challenges related to toxicity, cost, and access. The Series also explores the growing role of engineered cell therapies in haematological malignancies and solid tumours, emphasising Europe’s scientific leadership alongside regulatory and manufacturing barriers. Advances in immune engagement underscore a shift toward more precise and durable antitumour responses, while reinforcing the need for biomarker-guided patient selection and system-level solutions to translate innovation into equitable clinical benefit.
https://www.thelancet.com/series-do/cancer-therapies?dgcid=hubspot_update_feature_lanepecancertherapies26&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9Iv30TOsv86ubzEPvvi7y09sDdaNoJxYby5gKpAJq_uAuz1hIvQpGLf2MgjAH0enHrK161StJw5_-if2okpprLT1f70g&_hsmi=413587672&utm_content=413506161&utm_source=hs_email
European medicines agency approvals of new medicines in January and February 2026
Bruno Sepodesa,b ∙ Juan Garcia Burgosc ∙ Steffen Thirstrup
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00069-4/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9THJdPjb1atX04h2d9CGSxtNbidbKL6AHPyZO5Y7ErBrwLtOtjg9HCH8GafIDDrff_OPsoB5FAJ1yYWiF6U4RKGcIKkg&_hsmi=413587672&utm_content=413506161&utm_source=hs_email
Humanity first, not country first
The Lancet Regional Health – Europe
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00076-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz--v2vIxd72bJVaEkaNOXJ2X-9-cCUsdGPGZ3hn_zSKQL11EW4Lj7f0AxQnBKQ9qjNNIutT1d9ZcxapW9d9H0Zl_YrbV7A&_hsmi=413587672&utm_content=413506161&utm_source=hs_email
Apr 2026
Volume 63
https://www.thelancet.com/journals/lanepe/issue/vol63nonull/PIIS2666-7762(25)X0014-4
No hay comentarios:
Publicar un comentario